South Korea BPDCN Market Set to Nearly Double by 2034 — Forecast to Reach USD 85.78 Million Driven by Novel Therapies, Improved Diagnosis and Supportive Reimbursement
The South Korea blastic plasmacytoid dendritic cell neoplasm (BPDCN) market , valued at USD 42.88 million in 2024 , is forecast to expand at a compound annual growth rate (CAGR) of 7.20% between 2025 and 2034, reaching an estimated USD 85.78 million by 2034 . Growth will be propelled by improved disease awareness, advancements in targeted therapies, wider diagnostic adoption, and strengthened payer support for rare hematologic malignancies. Market overview / summary Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy originating from plasmacytoid dendritic cells. Historically characterized by poor prognosis and limited treatment options, BPDCN management has evolved over the last decade with the development of targeted agents, novel combination regimens, and better supportive care. The South Korean market—driven by a well-established oncology infrastructure, centralized tertiary-care centers, and robu...